标签： Jamaica

In early 2025, Gregory White, a 65-year-old man, experienced a sudden spike in blood pressure after using pesticide. This incident led him to seek medical attention, a decision that potentially saved his life. During the visit, his doctor inquired about his last prostate exam, which he had undergone two years prior. The doctor emphasized the importance of annual screenings, prompting further investigation. Initial blood tests showed normal prostate-specific antigen (PSA) levels, but subsequent tests revealed a slightly elevated PSA level of 5.6. Although a physical examination suggested no abnormalities, the doctor recommended additional testing to uncover the underlying issue. White was referred to urologist Dr. Dean Wong at Apex Medical Centre, where an MRI and biopsy confirmed a diagnosis of stage 2 prostate cancer. ‘I was concerned; I never expected that,’ White shared with Observer Online. ‘But knowing that it is there, I have to deal with it.’ After discussing treatment options with Dr. Wong, White chose surgery over radiation and underwent a radical prostatectomy in June. Post-surgery tests showed undetectable PSA levels, indicating successful cancer removal. Since the surgery, White has been engaged in functional rehabilitation, focusing on urinary continence and sexual function recovery. Dr. Wong highlighted the importance of early physiotherapy and the use of the Emsella chair, a specialized device for treating urinary incontinence and pelvic floor issues. White is also undergoing pelvic floor strengthening exercises, electromagnetic wave therapy, and sexual rehabilitation, including daily medication and the use of a penile vacuum pump. While he reports no pain from the surgery, urinary leakage remains a challenge. ‘I have to wear pull-ups,’ White admitted. ‘Last two months or month and a half ago I had to have a pad in the pull-ups to hold the urine, and if I’m physical during the day, I would change like three of those pads for the day. Now I’m down to one.’ Dr. Wong emphasized that post-surgery results evolve over time, with functional recovery typically assessed at one year. White remains optimistic about his prognosis as he continues his recovery journey.

In 2022, France introduced a groundbreaking strategy to combat endometriosis, a chronic condition affecting one in ten women of reproductive age worldwide. Central to this initiative was the promotion of the ‘Endotest,’ a saliva-based diagnostic tool developed by French start-up Ziwig. Marketed as a revolutionary solution leveraging artificial intelligence and microRNA technology, the test promised to simplify and expedite the diagnosis of endometriosis, which currently requires invasive surgical procedures. However, despite significant government backing and financial investment, questions linger about the test’s efficacy and broader applicability. Researchers have raised concerns about the limited scope of studies supporting the Endotest, with some arguing that the participant samples may not be representative of the general population. While the French Health Authority (HAS) has acknowledged the test’s diagnostic performance, it has also called for further research to confirm its clinical utility. Critics have pointed out the disproportionate funding allocated to the Endotest compared to other endometriosis research avenues, such as improving ultrasound interpretation. Patient advocacy groups like Endomind have campaigned for broader access to the test, but some patients and experts remain skeptical, questioning whether the Endotest truly represents a significant advancement in endometriosis care. Ziwig’s leadership defends the test, citing published research and ongoing efforts to validate its effectiveness through peer-reviewed journals. As the debate continues, the Endotest remains a focal point in France’s broader efforts to address the challenges of diagnosing and treating endometriosis.